Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2014

View Archived Issues

Novartis releases progress report from second quarter 2014

Vernalis and Tris Pharma achieve proof-of-concept for CCP-08

MRC Technology humanizes anti-tau monoclonal antibody for Axon Neuroscience

Epistem enters into collaborative funding agreement with GHIF for Genedrive platform and TB assay

Polaris Pharmaceuticals' ADI-PEG 20 obtains orphan drug status for mesothelioma

AOP Orphan conducting new trial in polycythemia vera

Biosceptre reports phase I results for BIL-010t in basal cell carcinoma

Advaxis and MedImmune partner on immunotherapy combination trial

Medigene's Trianta becomes project partner in German T-cell therapy collaborative research center

MODERN study of maraviroc regimen in HIV-1 infection does not meet primary endpoint

Alpharmagen describes novel alpha7-nAChR agonist

BioComo and Mie University present new hPIV2 vector-based vaccines

Puma reports topline results from phase III study of PB-272 in extended adjuvant breast cancer

Antisense Therapeutics reports data from phase I trial of ATL-1102

Bispecific, chimeric antibody-like immunoadhesin neutralizes HIV in vitro

New glycopeptide antibiotics disclosed by Chinese scientists

Vernalis and Lundbeck jointly patent novel LRRK2 inhibitors

Phase I/II safety data of a combination of a tuberculosis vaccine and antiretroviral therapy

Roche patents novel CDK8/cyclin-C inhibitors for cancer

Novel sigma1-receptor ligands disclosed by Esteve

FDA approves Ryanodex for treatment of malignant hyperthermia

Resverlogix reports MACE data in patients with diabetes treated with RVX-2018

UCB reports topline phase III results for brivaracetam in epilepsy

FDA approves Zydelig for three B-cell blood cancers

Plegridy approved in the E.U. for multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...